Overview: VEGF ELISA TestIntroduction: The VEGF ELISA Test measures vascular endothelial growth factor to diagnose cancer or vascular disorders, causing swelling. Following 2023 ASCO guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical diagnostics for patients with suspected malignancies or vascular issues. Note: Test Parameters and Sample Stability are not specified in input data; typically includes VEGF levels and standard stability.
Other Names: VEGF Assay, Vascular Endothelial Growth Factor Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical diagnostic standards for accuracy.
Historical Milestone: VEGF testing began in the 1990s with angiogenesis research. ELISA methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures VEGF to diagnose cancer or vascular disorders, guides treatment, and evaluates patients with swelling.
Test Parameters: Not specified in input data; typically includes VEGF levels.
Pretest Condition: No fasting required. Collect serum or plasma. Report history of swelling or cancer symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: Not specified in input data; typically 8 hours.
Sample Stability at Refrigeration: Not specified in input data; typically 7 days.
Sample Stability at Frozen: Not specified in input data; typically 6 months.
Medical History: Document swelling, tumors, or history of cancer or vascular disorders. Include current medications, especially anti-angiogenic drugs.
Consent: Written consent required, detailing the tests purpose, cancer or vascular disorder implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to measure VEGF levels. Results are available in 5-7 days, supporting clinical decisions. Performed in laboratories, often for cancer or vascular disorder diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Medications like bevacizumab may alter VEGF levels.
Clinical Significance: Elevated VEGF confirms cancer or vascular disorders, guiding anti-angiogenic therapy. Normal levels may require imaging or biopsy.
Specialist Consultation: Consult an oncologist or vascular specialist for result interpretation and treatment planning.
Additional Supporting Tests: Tumor markers, imaging, or biopsy to confirm cancer or vascular disorder diagnosis.
Test Limitations: Non-specific for cancer type; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Cancer Guidelines, 2023; Journal of Clinical Oncology, Ferrara N, 2022.
